River Vision Development Corporation

1 Rockefeller Plz Rm 1204, New York City, New York, United States

Clinical Trials

4 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

80.0%

Phase 2

20.0%

Trial Status Distribution

Active, not recruiting

80.0%

Withdrawn

20.0%

Clinical Trials

Trials sponsored by this organization (5)

A trial looking at the safety of RV 001 and how well it works in treating thyroid eye disease. The trial drug or placebo is given intravenously (into a vein) every 3 weeks and allocation to the study drug is by chance.

Phase 1

Active, not recruiting

Sep 201487 participants

A trial looking at the safety of RV 001 and how well it works in treating thyroid eye disease. The trial drug or placebo is given intravenously (into a vein) every 3 weeks and allocation to the study drug is by chance.

Phase 1

Active, not recruiting

Mar 201484 participants

A trial looking at the safety of RV 001 and how well it works in treating thyroid eye disease. The trial drug or placebo is given intravenously (into a vein) every 3 weeks and allocation to the study drug is by chance.

Phase 1

Active, not recruiting

Mar 201487 participants

A trial looking at the safety of RV 001 and how well it works in treating thyroid eye disease. The trial drug or placebo is given intravenously (into a vein) every 3 weeks and allocation to the study drug is by chance.

Phase 1

Active, not recruiting

Mar 201484 participants

A randomized, double-masked, placebo-controlled, efficacy and safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks (q3W) by intravenous (iv) infusion in patients suffering from active thyroid eye disease (TED)

Approvals

No approval data available

News

No news articles found

Back to Organizations